Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536704 · ClinicalTrials.gov registry record · Phase 1
Nicotine Lozenge Bioequivalence Study
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01536704 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants.
The verdict
NCT01536704, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
To compare the bio equivalence of new nicotine lozenge formulation with the reference nicotine lozenge so as to deliver the same nicotine blood profile.
Interventions
- DRUG Nicotine (2 mg)
- DRUG Nicotine (4 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536704
The ClinicalTrials.gov registry entry for NCT01536704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotine (2 mg) is the first listed.
NCT01536704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01536704 about?
NCT01536704 is a clinical study titled "Nicotine Lozenge Bioequivalence Study". To compare the bio equivalence of new nicotine lozenge formulation with the reference nicotine lozenge so as to deliver the same nicotine blood profile.
What is the current status of trial NCT01536704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2011-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01536704?
The interventions under investigation include: Nicotine (2 mg) (DRUG), Nicotine (4 mg) (DRUG).
Who is sponsoring clinical trial NCT01536704?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.